Adjusted for cell proportions: TRUE PR **PNR** PR - PNR pooled pooled pooled enriched in B cells (I) (LI.M47.0) enriched in B cells (II) (LI.M47.1) plasma cells & B cells, immunoglobulins (LI.M156.0) enriched in B cells (VI) (LI.M69) plasma cells, immunoglobulins (LI.M156.1) -B cell surface signature (LI.S2) enriched in T cells (I) (LI.M7.0) -T cell activation (I) (LI.M7.1) enriched in B cells (III) (LI.M47.2) enriched in NK cells (I) (LI.M7.2) -T cell activation (II) (LI.M7.3) enriched in antigen presentation (I) (LI.M71) -TBA (LI.M114.0) -MHC-TLR7-TLR8 cluster (LI.M146) -Gene module extracellular matrix (II) (LI.M2.1) -TBA (LI.M105) cell cycle and transcription (LI.M4.0) type I interferon response (LI.M127) platelet activation & blood coagulation (LI.M199) enriched in activated dendritic cells (II) (LI.M165) antiviral IFN signature (LI.M75) cell adhesion (LI.M51) platelet activation - actin binding (LI.M196) enriched in monocytes (IV) (LI.M118.0) -Monocyte surface signature (LI.S4) enriched in myeloid cells and monocytes (LI.M81) enriched in neutrophils (I) (LI.M37.1) -TLR and inflammatory signaling (LI.M16) enriched in monocytes (II) (LI.M11.0) immune activation - generic cluster (LI.M37.0) --log10(FDR)

Direction of effect

Down at week 14

Not significant

Up at week 14

Effect size (AUC)

0.5

0.9